Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genmab Lands Experienced Partner AbbVie In Broad Bispecific Antibody Collaboration

Executive Summary

AbbVie will pay $750m up front plus up to $3.15bn in milestone fees to jointly develop and commercialize three bispecific antibody candidates for cancer and an earlier drug discovery collaboration.

You may also be interested in...



Genmab Commercial Expansion Opens The Door To New Types Of Deals

The company's CEO talked to Scrip about the expected US launch of tisotumab vedotin likely later in 2021 and the company's partnering strategy going forward.

$2bn AbbVie Deal Puts I-Mab On Global Immuno-Oncology Map

In another clear signal that China's innovative drug R&D is coming of age, most global rights to I-Mab's promising early-stage CD47 antibody have been picked up by AbbVie in a deal valued at close to $2bn.

Dealmaking Quarterly Statistics, Q2 2020

During Q2 biopharmas reached $5.9bn in merger and acquisition value and drew in $44bn in potential deal value from alliances. Device company M&A values reached $159m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.4bn.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel